Browse by category

The initial results of a study assessing the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence, has reported that after 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. “These results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,” said

Innovent Biologics’ supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a hig

The oral GLP-1, orforglipron, can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by researchers from the University of Texas Health Science Center at Houston, TX. Orforglipron (Image credit: Jovan.gec) "The opportunity for an oral GLP-1 medication with highly effective weight loss that is simpler to take may provide increased access and opportunities fo

A case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention (LI) compared to LI alone, has found a significantly higher weight reduction, fat mass loss, and visceral fat loss in patients treated with the Allurion Smart Capsule combined with lifestyle intervention. At 36 weeks, Allurion Smart Capsule patients had an average weight reduction of 20% with favourable body composition changes. The Allurion Smart Capsule is designed to be sw

Viking Therapeutics has completed patient enrolment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. The Phase 3 VANQUISH-1 study is a randomised, double-blind, placebo-controlled, multi-centre t

A research team has developed a fluorescent probe that allows scientists to visualise how individual lipid droplets break down inside living cells in real-time. The probe changes its fluorescence properties depending on the chemical composition of each droplet, which allows researchers to observe not only their location within cells, but also their metabolic activity during lipid breakdown. The findings may contribute to the development of new strategies to treat metabolic di